{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:58:25Z","timestamp":1780441105988,"version":"3.54.1"},"reference-count":116,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Shenzhen Science and Technology Innovation Commission","award":["JCY20220530155613030"],"award-info":[{"award-number":["JCY20220530155613030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03913-0","type":"journal-article","created":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T13:51:39Z","timestamp":1738417899000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Targeting BCMA in multiple myeloma: designs, challenges, and future directions"],"prefix":"10.1007","volume":"74","author":[{"given":"Yi","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuetao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lufeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zugang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,1]]},"reference":[{"key":"3913_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348","journal-title":"CA Cancer J Clin"},{"key":"3913_CR2","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.3390\/curroncol30020179","volume":"30","author":"P Bhatt","year":"2023","unstructured":"Bhatt P, Kloock C, Comenzo R (2023) Relapsed\/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol 30:2322\u20132347","journal-title":"Curr Oncol"},{"key":"3913_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.canlet.2020.07.044","volume":"491","author":"Y Xie","year":"2020","unstructured":"Xie Y, Hu Y, Zhou N, Yao C, Wu L, Liu L, Chen F (2020) CAR T-cell therapy for triple-negative breast cancer: Where we are. Cancer Lett 491:121\u2013131","journal-title":"Cancer Lett"},{"key":"3913_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer JN (2021) CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol 18:71\u201384","journal-title":"Nat Rev Clin Oncol"},{"key":"3913_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jcyt.2019.12.004","volume":"22","author":"P Braendstrup","year":"2020","unstructured":"Braendstrup P, Levine BL, Ruella M (2020) The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19. Cytotherapy 22:57\u201369","journal-title":"Cytotherapy"},{"key":"3913_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11:1\u201311","journal-title":"Blood Cancer J"},{"key":"3913_CR7","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/febs.15523","volume":"288","author":"CU Zajc","year":"2021","unstructured":"Zajc CU, Salzer B, Taft JM, Reddy ST, Lehner M, Traxlmayr MW (2021) Driving CARs with alternative navigation tools\u2013the potential of engineered binding scaffolds. FEBS J 288:2103\u20132118","journal-title":"FEBS J"},{"key":"3913_CR8","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1073\/pnas.1817147116","volume":"116","author":"YJ Xie","year":"2019","unstructured":"Xie YJ, Dougan M, Jailkhani N et al (2019) Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci 116:7624\u20137631","journal-title":"Proc Natl Acad Sci"},{"key":"3913_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/cells11010021","volume":"11","author":"GM Branella","year":"2021","unstructured":"Branella GM, Spencer HT (2021) Natural receptor-and ligand-based chimeric antigen receptors: strategies using natural ligands and receptors for targeted cell killing. Cells 11:21","journal-title":"Cells"},{"key":"3913_CR10","doi-asserted-by":"publisher","first-page":"7439","DOI":"10.1182\/blood-2022-163827","volume":"140","author":"MJ Frigault","year":"2022","unstructured":"Frigault MJ, Bishop MR, Rosenblatt J et al (2022) Phase 1 Study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood 140:7439","journal-title":"Blood"},{"key":"3913_CR11","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40164-023-00373-7","volume":"12","author":"T Yan","year":"2023","unstructured":"Yan T, Zhu L, Chen J (2023) Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment. Exp Hematol Oncol 12:14","journal-title":"Exp Hematol Oncol"},{"key":"3913_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1146\/annurev-pharmtox-010814-124844","volume":"56","author":"G Gross","year":"2016","unstructured":"Gross G, Eshhar Z (2016) Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol 56:59\u201383","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3913_CR13","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","volume":"9","author":"S-F Cho","year":"2018","unstructured":"Cho S-F, Anderson KC, Tai Y-T (2018) Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front Immunol 9:1821","journal-title":"Front Immunol"},{"key":"3913_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"B Yu","year":"2020","unstructured":"Yu B, Jiang T, Liu D (2020) BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol 13:1\u201324","journal-title":"J Hematol Oncol"},{"key":"3913_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor BP, Raman VS, Erickson LD et al (2004) BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 199:91\u201398","journal-title":"J Exp Med"},{"key":"3913_CR16","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40265-022-01697-0","volume":"82","author":"B Paul","year":"2022","unstructured":"Paul B, Rodriguez C, Usmani SZ (2022) BCMA-targeted biologic therapies: the next standard of care in multiple myeloma therapy. Drugs 82:613","journal-title":"Drugs"},{"key":"3913_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2003-06-2043","volume":"103","author":"AJ Novak","year":"2004","unstructured":"Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, Kindsvogel W, Gross JA, Greipp PR, Jelinek DF (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103:689\u2013694","journal-title":"Blood"},{"key":"3913_CR18","first-page":"3225","volume":"127","author":"Y-T Tai","year":"2016","unstructured":"Tai Y-T, Acharya C, An G et al (2016) APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood J Am Soc Hematol 127:3225\u20133236","journal-title":"Blood J Am Soc Hematol"},{"key":"3913_CR19","first-page":"103378","volume":"71","author":"Y Shen","year":"2023","unstructured":"Shen Y, Liu J, Wang B et al (2023) Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy. Curr Res Transl Med 71:103378","journal-title":"Curr Res Transl Med"},{"key":"3913_CR20","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","volume":"34","author":"N Shah","year":"2020","unstructured":"Shah N, Chari A, Scott E, Mezzi K, Usmani SZ (2020) B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34:985\u20131005","journal-title":"Leukemia"},{"key":"3913_CR21","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/ajh.25108","volume":"93","author":"J Cao","year":"2018","unstructured":"Cao J, Wang G, Cheng H et al (2018) Potent anti-leukemia activities of humanized CD19-targeted Chimeric antigen receptor T (CAR-T) cells in patients with relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol 93:851\u2013858","journal-title":"Am J Hematol"},{"key":"3913_CR22","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1158\/1078-0432.CCR-19-0916","volume":"25","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Liu Z, Wang X et al (2019) Treatment with humanized selective CD19CAR-T cells shows efficacy in highly treated B-ALL patients who have relapsed after receiving murine-based CD19CAR-T therapies. Clin Cancer Res 25:5595\u20135607","journal-title":"Clin Cancer Res"},{"key":"3913_CR23","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1200\/JCO.20.03458","volume":"39","author":"RM Myers","year":"2021","unstructured":"Myers RM, Li Y, Barz Leahy A et al (2021) Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia. J Clin Oncol 39:3044\u20133055","journal-title":"J Clin Oncol"},{"key":"3913_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12885-022-09489-1","volume":"22","author":"L An","year":"2022","unstructured":"An L, Lin Y, Deng B et al (2022) Humanized CD19 CAR-T cells in relapsed\/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy. BMC Cancer 22:393","journal-title":"BMC Cancer"},{"key":"3913_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-020-01001-1","volume":"13","author":"G Roex","year":"2020","unstructured":"Roex G, Timmers M, Wouters K et al (2020) Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. J Hematol Oncol 13:1\u201314","journal-title":"J Hematol Oncol"},{"key":"3913_CR26","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1089\/hum.2018.001","volume":"29","author":"KM Friedman","year":"2018","unstructured":"Friedman KM, Garrett TE, Evans JW, Horton HM, Latimer HJ, Seidel SL, Horvath CJ, Morgan RA (2018) Effective targeting of multiple B-cell maturation antigen\u2013expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum Gene Ther 29:585\u2013601","journal-title":"Hum Gene Ther"},{"key":"3913_CR27","doi-asserted-by":"crossref","unstructured":"Anderson J, Larry D, Munshi NC, Shah N et al (2021) Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results","DOI":"10.1200\/JCO.2021.39.15_suppl.8016"},{"key":"3913_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Anderson J, Larry D, Shah N et al (2020) Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): initial KarMMa results. Am Soc Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.8503","journal-title":"Am Soc Clin Oncol"},{"key":"3913_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384:705\u2013716","journal-title":"N Engl J Med"},{"key":"3913_CR30","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B et al (2023) Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 388:1002\u20131014","journal-title":"N Engl J Med"},{"key":"3913_CR31","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1182\/blood-2020-137156","volume":"136","author":"M Delforge","year":"2020","unstructured":"Delforge M, Baz RC, Cavo M et al (2020) KarMMa-3: a phase 3 study of idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy vs standard regimens in relapsed and refractory multiple myeloma. Blood 136:24\u201325","journal-title":"Blood"},{"key":"3913_CR32","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1038\/s41375-021-01269-3","volume":"35","author":"L Han","year":"2021","unstructured":"Han L, Zhang J-S, Zhou J et al (2021) Single VHH-directed BCMA CAR-T cells cause remission of relapsed\/refractory multiple myeloma. Leukemia 35:3002\u20133006","journal-title":"Leukemia"},{"key":"3913_CR33","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1016\/j.clml.2019.09.267","volume":"19","author":"XF Fan","year":"2019","unstructured":"Fan XF, Zhuang Q, Yang L, Hao J, Zhao D, Zhao Y, Wang P, Geng D (2019) Preclinical assessment of LCAR-B38M, a novel BCMA-targeting chimeric antigen receptor (CAR)-T cell therapy in relapsed\/refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 19:e160","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3913_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/biom11020238","volume":"11","author":"C Bao","year":"2021","unstructured":"Bao C, Gao Q, Li L et al (2021) The application of nanobody in CAR-T therapy. Biomolecules 11:238","journal-title":"Biomolecules"},{"key":"3913_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-021-00332-6","volume":"9","author":"Y Asaadi","year":"2021","unstructured":"Asaadi Y, Jouneghani FF, Janani S, Rahbarizadeh F (2021) A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomarker Res 9:1\u201320","journal-title":"Biomarker Res"},{"key":"3913_CR36","doi-asserted-by":"publisher","first-page":"3273","DOI":"10.1074\/jbc.M806889200","volume":"284","author":"C Vincke","year":"2009","unstructured":"Vincke C, Loris R, Saerens D, Martinez-Rodriguez S, Muyldermans S, Conrath K (2009) General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 284:3273\u20133284","journal-title":"J Biol Chem"},{"key":"3913_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0681-6","volume":"11","author":"W-H Zhao","year":"2018","unstructured":"Zhao W-H, Liu J, Wang B-Y et al (2018) A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma. J Hematol Oncol 11:1\u20138","journal-title":"J Hematol Oncol"},{"key":"3913_CR38","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1182\/blood-2019-124953","volume":"134","author":"B-Y Wang","year":"2019","unstructured":"Wang B-Y, Zhao W-H, Liu J et al (2019) Long-term follow-up of a phase 1, first-in-human open-label study of LCAR-B38M, a structurally differentiated chimeric antigen receptor T (CAR-T) cell therapy targeting B-cell maturation antigen (BCMA), in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). Blood 134:579","journal-title":"Blood"},{"key":"3913_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-022-01301-8","volume":"15","author":"W-H Zhao","year":"2022","unstructured":"Zhao W-H, Wang B-Y, Chen L-J et al (2022) Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol Oncol 15:1\u201312","journal-title":"J Hematol Oncol"},{"key":"3913_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","volume":"10","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S, Safarzadeh Kozani P (2022) Nanobody-based CAR-T cells for cancer immunotherapy. Biomarker Res 10:24","journal-title":"Biomarker Res"},{"key":"3913_CR41","doi-asserted-by":"publisher","first-page":"8028","DOI":"10.1200\/JCO.2022.40.16_suppl.8028","volume":"40","author":"SZ Usmani","year":"2022","unstructured":"Usmani SZ, Martin TG, Berdeja JG et al (2022) Phase 1b\/2 study of ciltacabtagene autoleucel, a BCMA-directed CAR-T cell therapy, in patients with relapsed\/refractory multiple myeloma (CARTITUDE-1): two years post-LPI. Am Soc Clin Oncol 40:8028","journal-title":"Am Soc Clin Oncol"},{"key":"3913_CR42","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. The Lancet 398:314\u2013324","journal-title":"The Lancet"},{"key":"3913_CR43","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K et al (2023) Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. New Engl J Med 389:335","journal-title":"New Engl J Med"},{"key":"3913_CR44","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41467-019-14119-9","volume":"11","author":"N Lam","year":"2020","unstructured":"Lam N, Trinklein ND, Buelow B, Patterson GH, Ojha N, Kochenderfer JN (2020) Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains. Nat Commun 11:283","journal-title":"Nat Commun"},{"key":"3913_CR45","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1182\/blood-2020-138839","volume":"136","author":"L Mikkilineni","year":"2020","unstructured":"Mikkilineni L, Manasanch EE, Vanasse D et al (2020) Deep and durable remissions of relapsed multiple myeloma on a first-in-humans clinical trial of T cells expressing an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) with a fully-human heavy-chain-only antigen recognition domain. Blood 136:50\u201351","journal-title":"Blood"},{"key":"3913_CR46","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ymthe.2023.12.018","volume":"32","author":"L Mikkilineni","year":"2024","unstructured":"Mikkilineni L, Natrakul DA, Lam N et al (2024) Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain. Mol Ther 32:503\u2013526","journal-title":"Mol Ther"},{"key":"3913_CR47","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1093\/protein\/gzr064","volume":"25","author":"SA Jacobs","year":"2012","unstructured":"Jacobs SA, Diem MD, Luo J, Teplyakov A, Obmolova G, Malia T, Gilliland GL, O\u2019Neil KT (2012) Design of novel FN3 domains with high stability by a consensus sequence approach. Protein Eng Des Sel 25:107\u2013117","journal-title":"Protein Eng Des Sel"},{"key":"3913_CR48","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1182\/blood.V128.22.2127.2127","volume":"128","author":"DL Hermanson","year":"2016","unstructured":"Hermanson DL, Barnett BE, Rengarajan S et al (2016) A novel BCMA-specific, centyrin-based CAR-T product for the treatment of multiple myeloma. Blood 128:2127","journal-title":"Blood"},{"key":"3913_CR49","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/antib10020013","volume":"10","author":"X Zhong","year":"2021","unstructured":"Zhong X, D\u2019Antona AM (2021) Recent advances in the molecular design and applications of multispecific biotherapeutics. Antibodies 10:13","journal-title":"Antibodies"},{"key":"3913_CR50","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1182\/blood-2019-129562","volume":"134","author":"CL Costello","year":"2019","unstructured":"Costello CL, Gregory TK, Ali SA et al (2019) Phase 2 study of the response and safety of P-Bcma-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM)(PRIME). Blood 134:3184","journal-title":"Blood"},{"key":"3913_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1182\/blood-2020-142695","volume":"136","author":"CL Costello","year":"2020","unstructured":"Costello CL, Cohen AD, Patel KK et al (2020) Phase 1\/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with relapsed\/refractory (r\/r) multiple myeloma (MM)(PRIME) with novel therapeutic strategies. Blood 136:29\u201330","journal-title":"Blood"},{"key":"3913_CR52","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1182\/blood-2021-151672","volume":"138","author":"C Costello","year":"2021","unstructured":"Costello C, Derman BA, Kocoglu MH et al (2021) Clinical trials of BCMA-targeted CAR-T cells utilizing a novel non-viral transposon system. Blood 138:3858","journal-title":"Blood"},{"key":"3913_CR53","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1182\/blood-2019-131839","volume":"134","author":"SA Cranert","year":"2019","unstructured":"Cranert SA, Richter M, Tong M, Weiss L, Tan Y, Ostertag EM, Coronella J, Shedlock DJ (2019) Manufacture of an allogeneic CAR-T stem cell memory product candidate for multiple myeloma, P-Bcma-ALLO1, is robust, reproducible and highly scalable. Blood 134:4445","journal-title":"Blood"},{"key":"3913_CR54","doi-asserted-by":"publisher","first-page":"100152","DOI":"10.1016\/j.iotech.2022.100152","volume":"16","author":"M Kocoglu","year":"2022","unstructured":"Kocoglu M, Asch A, Ramakrishnan A et al (2022) 47P Phase I study to assess the safety and efficacy of P-BCMA-ALLO1: a fully allogeneic CAR-T therapy, in patients with relapsed\/refractory multiple myeloma (RRMM). Immuno-Oncol Technol 16:100152","journal-title":"Immuno-Oncol Technol"},{"key":"3913_CR55","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.beha.2018.03.003","volume":"31","author":"JM Murad","year":"2018","unstructured":"Murad JM, Graber DJ, Sentman CL (2018) Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies. Best Pract Res Clin Haematol 31:176\u2013183","journal-title":"Best Pract Res Clin Haematol"},{"key":"3913_CR56","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1182\/bloodadvances.2019000703","volume":"3","author":"A Schmidts","year":"2019","unstructured":"Schmidts A, Ormh\u00f8j M, Choi BD et al (2019) Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv 3:3248\u20133260","journal-title":"Blood Adv"},{"key":"3913_CR57","first-page":"746","volume":"131","author":"L Lee","year":"2018","unstructured":"Lee L, Draper B, Chaplin N et al (2018) An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma. Blood J Am Soc Hematol 131:746\u2013758","journal-title":"Blood J Am Soc Hematol"},{"key":"3913_CR58","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1182\/blood-2019-126689","volume":"134","author":"R Popat","year":"2019","unstructured":"Popat R, Zweegman S, Cavet J et al (2019) Phase 1 first-in-human study of AUTO2, the first chimeric antigen receptor (CAR) T cell targeting APRIL for patients with relapsed\/refractory multiple myeloma (RRMM). Blood 134:3112","journal-title":"Blood"},{"key":"3913_CR59","doi-asserted-by":"publisher","first-page":"e006699","DOI":"10.1136\/jitc-2023-006699","volume":"11","author":"L Lee","year":"2023","unstructured":"Lee L, Lim WC, Galas-Filipowicz D et al (2023) Limited efficacy of APRIL CAR in patients with multiple myeloma indicate challenges in the use of natural ligands for CAR T-cell therapy. J Immunother Cancer 11:e006699","journal-title":"J Immunother Cancer"},{"key":"3913_CR60","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/blood-2018-99-119633","volume":"132","author":"A Schmidts","year":"2018","unstructured":"Schmidts A, Ormhoj M, Taylor AO, Lorrey SJ, Scarf\u00f2 I, Frigault MJ, Choi BD, Maus MV (2018) Engineering an optimized trimeric APRIL-based CAR to broaden targetability of multiple myeloma. Blood 132:2059","journal-title":"Blood"},{"key":"3913_CR61","doi-asserted-by":"publisher","first-page":"e005091","DOI":"10.1136\/jitc-2022-005091","volume":"10","author":"N Camviel","year":"2022","unstructured":"Camviel N, Wolf B, Croce G, Gfeller D, Zoete V, Arber C (2022) Both APRIL and antibody-fragment-based CAR T cells for myeloma induce BCMA downmodulation by trogocytosis and internalization. J Immunother Cancer 10:e005091","journal-title":"J Immunother Cancer"},{"key":"3913_CR62","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.ymthe.2019.04.010","volume":"27","author":"H Qin","year":"2019","unstructured":"Qin H, Edwards JP, Zaritskaya L, Gupta A, Mu CJ, Fry TJ, Hilbert DM, LaFleur DW (2019) Chimeric antigen receptors incorporating D domains targeting CD123 direct potent mono-and bi-specific antitumor activity of T cells. Mol Ther 27:1262\u20131274","journal-title":"Mol Ther"},{"key":"3913_CR63","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1158\/1535-7163.MCT-21-0552","volume":"21","author":"JM Buonato","year":"2022","unstructured":"Buonato JM, Edwards JP, Zaritskaya L, Witter AR, Gupta A, LaFleur DW, Tice DA, Richman LK, Hilbert DM (2022) Preclinical efficacy of bcma-directed car T cells incorporating a novel d domain antigen recognition domain. Mol Cancer Ther 21:1171\u20131183","journal-title":"Mol Cancer Ther"},{"key":"3913_CR64","unstructured":"Buonato JM, Edwards J, Zaritskaya L, Gupta A, Richman L, Hilbert D, LaFleur D, Tice D (2021) Design and demonstration of potent in vitro and in vivo activity for CART ddBCMA, a BCMA targeted CAR T cell therapy incorporating a non scFv binding domain. In: ASGCT virtual meeting. Virtual"},{"key":"3913_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(22)00276-2","author":"MJ Frigault","year":"2021","unstructured":"Frigault MJ, O\u2019Donnell E, Raje NS et al (2021) Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leukemia. https:\/\/doi.org\/10.1016\/S2152-2650(22)00276-2","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"3913_CR66","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1182\/bloodadvances.2022007210","volume":"7","author":"MJ Frigault","year":"2023","unstructured":"Frigault MJ, Bishop MR, Rosenblatt J et al (2023) Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. Blood Adv 7:768\u2013777","journal-title":"Blood Adv"},{"key":"3913_CR67","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood-2023-189761","volume":"142","author":"MJ Frigault","year":"2023","unstructured":"Frigault MJ, Rosenblatt J, Dhakal B et al (2023) Phase 1 study of CART-Ddbcma for the treatment of patients with relapsed and\/or refractory multiple myeloma: results from at least 1-year follow-up in all patients. Blood 142:1023","journal-title":"Blood"},{"key":"3913_CR68","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL (2018) Tumor antigen escape from CAR T-cell therapy. Cancer Discov 8:1219\u20131226","journal-title":"Cancer Discov"},{"key":"3913_CR69","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11899-019-00537-5","volume":"14","author":"Z Walsh","year":"2019","unstructured":"Walsh Z, Ross S, Fry TJ (2019) Multi-specific CAR targeting to prevent antigen escape. Curr Hematol Malig Rep 14:451\u2013459","journal-title":"Curr Hematol Malig Rep"},{"key":"3913_CR70","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/2643-3230.BCD-20-0122","volume":"1","author":"S Simon","year":"2020","unstructured":"Simon S, Riddell SR (2020) Dual targeting with CAR T cells to limit antigen escape in multiple myeloma. Blood Cancer Discov 1:130\u2013133","journal-title":"Blood Cancer Discov"},{"key":"3913_CR71","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A et al (2021) Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 12:868","journal-title":"Nat Commun"},{"key":"3913_CR72","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R et al (2023) Mechanisms of antigen escape from BCMA-or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 29:2295","journal-title":"Nat Med"},{"key":"3913_CR73","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1182\/blood-2019-129582","volume":"134","author":"DJ Green","year":"2019","unstructured":"Green DJ, Pont M, Cowan AJ et al (2019) Response to Bcma CAR-T cells correlates with pretreatment target antigen density and is improved by small molecule inhibition of gamma secretase. Blood 134:1856","journal-title":"Blood"},{"key":"3913_CR74","first-page":"1585","volume":"134","author":"MJ Pont","year":"2019","unstructured":"Pont MJ, Hill T, Cole GO et al (2019) \u03b3-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood J Am Soc Hematol 134:1585\u20131597","journal-title":"Blood J Am Soc Hematol"},{"key":"3913_CR75","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1470-2045(23)00246-2","volume":"24","author":"AJ Cowan","year":"2023","unstructured":"Cowan AJ, Pont MJ, Sather BD et al (2023) \u03b3-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol 24:811\u2013822","journal-title":"Lancet Oncol"},{"key":"3913_CR76","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2022-168903","volume":"140","author":"MK Samur","year":"2022","unstructured":"Samur MK, Martin N, Thompson E, Fulciniti M, Aktas-Samur A, Kaiser S, Munshi NC (2022) Differences in single cells between BCMA-targeting CAR T-cell therapy responders and non-responders reveals initial resistance and acquired resistance are driven by different factors. Blood 140:2106\u20132107","journal-title":"Blood"},{"key":"3913_CR77","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R et al (2023) Mechanisms of antigen escape from BCMA-or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med 29:2295\u20132306","journal-title":"Nat Med"},{"key":"3913_CR78","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40164-023-00402-5","volume":"12","author":"W Li","year":"2023","unstructured":"Li W, Zhang B, Cao W et al (2023) Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed\/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol 12:44","journal-title":"Exp Hematol Oncol"},{"key":"3913_CR79","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12185-022-03365-1","volume":"115","author":"K Ohmine","year":"2022","unstructured":"Ohmine K, Uchibori R (2022) Novel immunotherapies in multiple myeloma. Int J Hematol 115:799","journal-title":"Int J Hematol"},{"key":"3913_CR80","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.15917","author":"J Padda","year":"2021","unstructured":"Padda J, Khalid K, Zubair U, Peethala MM, Kakani V, Goriparthi L, Almanie AH, Cooper AC, Jean-Charles G (2021) Chimeric antigen receptor T cell therapy and its significance in multiple myeloma. Cureus. https:\/\/doi.org\/10.7759\/cureus.15917","journal-title":"Cureus"},{"key":"3913_CR81","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1182\/blood-2019-130340","volume":"134","author":"C Li","year":"2019","unstructured":"Li C, Mei H, Hu Y et al (2019) A bispecific CAR-T cell therapy targeting Bcma and CD38 for relapsed\/refractory multiple myeloma: updated results from a phase 1 dose-climbing trial. Blood 134:930","journal-title":"Blood"},{"key":"3913_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-021-01170-7","volume":"14","author":"H Mei","year":"2021","unstructured":"Mei H, Li C, Jiang H et al (2021) A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol 14:1\u201317","journal-title":"J Hematol Oncol"},{"key":"3913_CR83","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan Z, Cao J, Cheng H et al (2019) A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol 6:e521\u2013e529","journal-title":"Lancet Haematol"},{"key":"3913_CR84","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/cam4.3624","volume":"10","author":"L Yan","year":"2021","unstructured":"Yan L, Qu S, Shang J et al (2021) Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and\/or refractory myeloma. Cancer Med 10:563\u2013574","journal-title":"Cancer Med"},{"key":"3913_CR85","first-page":"323","volume":"137","author":"J Gauthier","year":"2021","unstructured":"Gauthier J, Bezerra ED, Hirayama AV et al (2021) Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood J Am Soc Hematol 137:323\u2013335","journal-title":"Blood J Am Soc Hematol"},{"key":"3913_CR86","doi-asserted-by":"publisher","first-page":"8014","DOI":"10.1200\/JCO.2021.39.15_suppl.8014","volume":"39","author":"H Jiang","year":"2021","unstructured":"Jiang H, Dong B, Gao L et al (2021) Long-term follow-up results of a multicenter first-in-human study of the dual BCMA\/CD19 Targeted FasT CAR-T GC012F for patients with relapsed\/refractory multiple myeloma. J Clin Oncol 39:8014","journal-title":"J Clin Oncol"},{"key":"3913_CR87","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.1200\/JCO.2022.40.16_suppl.8005","volume":"16","author":"J Du","year":"2022","unstructured":"Du J, Jiang H, Dong B et al (2022) Updated results of a multicenter first-in-human study of BCMA\/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM). J Cli Oncol 16:8005","journal-title":"J Cli Oncol"},{"key":"3913_CR88","doi-asserted-by":"publisher","first-page":"8005","DOI":"10.1200\/JCO.2023.41.16_suppl.8005","volume":"16","author":"J Du","year":"2023","unstructured":"Du J, Fu W, Jiang H et al (2023) Updated results of a Phase I, open-label study of BCMA\/CD19 Dual-targeting FasTCAR-T GC012F for patients with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol 16:8005","journal-title":"J Clin Oncol"},{"key":"3913_CR89","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2023-174841","volume":"142","author":"J Du","year":"2023","unstructured":"Du J, Qiang W, Lu J et al (2023) Updated results of a phase I open-label single-arm study of dual targeting BCMA and CD19 Fastcar-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma. Blood 142:1022","journal-title":"Blood"},{"key":"3913_CR90","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C Fern\u00e1ndez de Larrea","year":"2020","unstructured":"Fern\u00e1ndez de Larrea C, Staehr M, Lopez AV et al (2020) Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape\u2013driven relapse in multiple myeloma. Blood Cancer Discovry 1:146\u2013154","journal-title":"Blood Cancer Discovry"},{"key":"3913_CR91","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/S2352-3026(24)00176-5","volume":"11","author":"D Zhou","year":"2024","unstructured":"Zhou D, Sun Q, Xia J et al (2024) Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Lancet Haematol 11:751","journal-title":"Lancet Haematol"},{"key":"3913_CR92","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","volume":"12","author":"AD Cohen","year":"2022","unstructured":"Cohen AD, Parekh S, Santomasso BD et al (2022) Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 12:32","journal-title":"Blood Cancer J"},{"key":"3913_CR93","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","volume":"27","author":"O Van Oekelen","year":"2021","unstructured":"Van Oekelen O, Aleman A, Upadhyaya B et al (2021) Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med 27:2099\u20132103","journal-title":"Nat Med"},{"key":"3913_CR94","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1182\/blood.2024024166","volume":"143","author":"M Elsallab","year":"2024","unstructured":"Elsallab M, Ellithi M, Lunning MA, D\u2019Angelo C, Ma J, Perales M-A, Frigault M, Maus MV (2024) Second primary malignancies after commercial CAR T cell therapy: analysis of FDA adverse events reporting system (FAERS). Blood. 143:3099","journal-title":"Blood."},{"key":"3913_CR95","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN et al (2024) T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med 30:984","journal-title":"Nat Med"},{"key":"3913_CR96","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","volume":"4","author":"BL Levine","year":"2017","unstructured":"Levine BL, Miskin J, Wonnacott K, Keir C (2017) Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev 4:92\u2013101","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3913_CR97","doi-asserted-by":"publisher","first-page":"16015","DOI":"10.1038\/mto.2016.15","volume":"3","author":"X Wang","year":"2016","unstructured":"Wang X, Rivi\u00e8re I (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncol 3:16015","journal-title":"Mol Ther Oncol"},{"key":"3913_CR98","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2326-6066.CIR-17-0405","volume":"6","author":"S Ghassemi","year":"2018","unstructured":"Ghassemi S, Nunez-Cruz S, O\u2019Connor RS et al (2018) Reducing ex vivo culture improves the antileukemic activity of chimeric antigen receptor (CAR) T cells. Cancer Immunol Res 6:1100\u20131109","journal-title":"Cancer Immunol Res"},{"key":"3913_CR99","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41408-022-00694-6","volume":"12","author":"J Yang","year":"2022","unstructured":"Yang J, He J, Zhang X et al (2022) Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study. Blood Cancer J 12:104","journal-title":"Blood Cancer J"},{"key":"3913_CR100","doi-asserted-by":"publisher","first-page":"E322","DOI":"10.1002\/ajh.25630","volume":"94","author":"S Tu","year":"2019","unstructured":"Tu S, Huang R, Guo Z et al (2019) Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome. Am J Hematol 94:E322\u2013E325","journal-title":"Am J Hematol"},{"key":"3913_CR101","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1182\/blood.V130.Suppl_1.886.886","volume":"130","author":"P Kebriaei","year":"2017","unstructured":"Kebriaei P, Huls H, Neel SL et al (2017) Shortening the time to manufacture CAR+ T cells with sleeping beauty system supports T-cell engraftment and anti-tumor effects in patients with refractory CD19+ tumors. Blood 130:2060","journal-title":"Blood"},{"key":"3913_CR102","first-page":"25","volume":"136","author":"H Jiang","year":"2020","unstructured":"Jiang H, Dong B, Gao L et al (2020) Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform fast CAR-T cell therapy for patients with relapsed\/refractory multiple myeloma. Blood 136:25\u201326","journal-title":"Blood"},{"key":"3913_CR103","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1182\/blood-2022-162295","volume":"140","author":"J Du","year":"2022","unstructured":"Du J, Fu W, Lu J et al (2022) Phase I open-label single-arm study of BCMA\/CD19 dual-targeting FasTCAR-T Cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma. Blood 140:889\u2013890","journal-title":"Blood"},{"key":"3913_CR104","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1182\/blood-2021-146646","volume":"138","author":"AS Sperling","year":"2021","unstructured":"Sperling AS, Nikiforow S, Nadeem O et al (2021) Phase I study of PHE885, a fully human BCMA-directed CAR-T cell therapy for relapsed\/refractory multiple myeloma manufactured in< 2 days using the T-charge TM platform. Blood 138:3864","journal-title":"Blood"},{"key":"3913_CR105","doi-asserted-by":"publisher","first-page":"8004","DOI":"10.1200\/JCO.2023.41.16_suppl.8004","volume":"41","author":"AS Sperling","year":"2023","unstructured":"Sperling AS, Derman BA, Nikiforow S et al (2023) Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r\/r multiple myeloma (RRMM). Am Soc Clin Oncol 41:8004","journal-title":"Am Soc Clin Oncol"},{"key":"3913_CR106","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s12026-020-09119-7","volume":"68","author":"MH Townsend","year":"2020","unstructured":"Townsend MH, Bennion K, Robison RA, O\u2019Neill KL (2020) Paving the way towards universal treatment with allogenic T cells. Immunol Res 68:63\u201370","journal-title":"Immunol Res"},{"key":"3913_CR107","doi-asserted-by":"publisher","first-page":"e86","DOI":"10.1002\/acg2.86","volume":"3","author":"BT Aftab","year":"2020","unstructured":"Aftab BT, Sasu B, Krishnamurthy J, Gschweng E, Alcazer V, Depil S (2020) Toward \u201coff-the-shelf\u201d allogeneic CAR T cells. Advances in Cell and Gene Therapy 3:e86","journal-title":"Advances in Cell and Gene Therapy"},{"key":"3913_CR108","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/biom10020263","volume":"10","author":"DW Kim","year":"2020","unstructured":"Kim DW, Cho J-Y (2020) Recent advances in allogeneic CAR-T cells. Biomolecules 10:263","journal-title":"Biomolecules"},{"key":"3913_CR109","doi-asserted-by":"publisher","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","volume":"54","author":"S Manier","year":"2022","unstructured":"Manier S, Ingegnere T, Escure G, Prodhomme C, Nudel M, Mitra S, Facon T (2022) Current state and next-generation CAR-T cells in multiple myeloma. Blood Rev 54:100929","journal-title":"Blood Rev"},{"key":"3913_CR110","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2021-145572","volume":"138","author":"S Mailankody","year":"2021","unstructured":"Mailankody S, Liedtke M, Sidana S et al (2021) Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed\/refractory multiple myeloma. Blood 138:651","journal-title":"Blood"},{"key":"3913_CR111","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11899-019-00528-6","volume":"14","author":"A Nianias","year":"2019","unstructured":"Nianias A, Themeli M (2019) Induced pluripotent stem cell (iPSC)\u2013derived lymphocytes for adoptive cell immunotherapy: recent advances and challenges. Curr Hematol Malig Rep 14:261\u2013268","journal-title":"Curr Hematol Malig Rep"},{"key":"3913_CR112","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s11095-021-03067-z","volume":"38","author":"M Sadeqi Nezhad","year":"2021","unstructured":"Sadeqi Nezhad M, Abdollahpour-Alitappeh M, Rezaei B, Yazdanifar M, Seifalian AM (2021) Induced pluripotent stem cells (iPSCs) provide a potentially unlimited T cell source for CAR-T cell development and off-the-shelf products. Pharm Res 38:931\u2013945","journal-title":"Pharm Res"},{"key":"3913_CR113","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/intimm\/dxab091","volume":"33","author":"H Kawamoto","year":"2021","unstructured":"Kawamoto H, Masuda K, Nagano S (2021) Regeneration of antigen-specific T cells by using induced pluripotent stem cell (iPSC) technology. Int Immunol 33:827\u2013833","journal-title":"Int Immunol"},{"key":"3913_CR114","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-142750","volume":"136","author":"JP Goodridge","year":"2020","unstructured":"Goodridge JP, Bjordahl R, Mahmood S et al (2020) FT576: multi-specific off-the-shelf CAR-NK cell therapy engineered for enhanced persistence, avoidance of self-fratricide and optimized mab combination therapy to prevent antigenic escape and elicit a deep and durable response in multiple myeloma. Blood 136:4\u20135","journal-title":"Blood"},{"key":"3913_CR115","doi-asserted-by":"publisher","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang H, Lan H, Wu J, Xiao Y (2023) CAR-T cell therapy in multiple myeloma: current limitations and potential strategies. Front Immunol 14:1101495","journal-title":"Front Immunol"},{"key":"3913_CR116","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.3390\/jcm11092513","volume":"11","author":"V Desantis","year":"2022","unstructured":"Desantis V, Savino FD, Scaringella A, Potenza MA, Nacci C, Frassanito MA, Vacca A, Montagnani M (2022) The leading role of the immune microenvironment in multiple myeloma: a new target with a great prognostic and clinical value. J Clin Med 11:2513","journal-title":"J Clin Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03913-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03913-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03913-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:22:32Z","timestamp":1741018952000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03913-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,1]]},"references-count":116,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["3913"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03913-0","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,1]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved to publish this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"77"}}